BioSpring and Phenion receive BMBF-Funding for the development of a bioactive for skin treatment
The Frankfurt-based Biotech companies BioSpring GmbH and Phenion GmbH & Co. KG receive public funding of approximately 1 million Euro within the "BioChancePlus" funding program of the German Federal Ministry of education and Research (BMBF). The objective of the common research project is the development of nucleic acid derivatives (oligonucleotides) as topical bioactives for skin calming and treatment of inflamed skin.
During the project oligonucleotide molecules will be synthesized and characterized regarding to their biological activity in the skin within the Phenion®-Full Thickness Skin Model. For further development of suitable oligonucleotides the companies will search a strategic partnership e.g. with the pharmaceutical industry.
Most read news
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

New x-ray method for Corona diagnosis ready for patient testing - Low-dose radiographs could reveal typical lung changes
New bacterial defense mechanism of the CRISPR-Cas system uncovered
ERBI unveils new name and brand identity: One Nucleus

Atomic insights into plant growth - Researchers from Tübingen resolve how a plant steroid hormone makes plants grow
Changes in biotech regulations must not be an attempt to further delay the approvals process
Category:Transmembrane_proteins
Researcher invents lethal 'lint brush' to capture and kill cancer cells in the bloodstream
